ArticleClinical rheumatology2026
Association between sex-hormone binding globulin and cardiovascular events in patients with rheumatoid arthritis.
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundRheumatoid arthritis (RA) is a common systemic autoimmune disease characterized by progressive deterioration of bone and cartilage. Sex hormone-binding globulin (SHBG), a glycoprotein integral to the regulation of sex hormone bioavailability, may have a pivotal role in the pathogenesis of RA. This study aims to investigate the relationship between SHBG concentrations and the risk of RA, as well as the occurrence of related cardiovascular complications.
methodsThe analysis included 25,051 adult participants from the National Health and Nutrition Examination Survey (NHANES) conducted between 2013 and 2023. Frailty was assessed using a 49-item frailty index, while medical conditions were self-reported via questionnaire. Logistic regression and mediation analyses were employed to evaluate these associations. Additionally, Kaplan-Meier survival curves were constructed to compare survival probabilities across different subgroups.
resultsElevated SHBG levels were identified as a significant risk factor for RA. Both the frailty index and C-reactive protein (CRP) levels demonstrated positive correlations with RA. Importantly, the frailty index partially mediated the association between SHBG and RA, accounting for approximately 24.47% of this relationship. Furthermore, RA patients with higher SHBG concentrations exhibited markedly reduced survival rates, an effect that was especially pronounced in male patients.
conclusionsSerum SHBG concentrations are inversely correlated with survival outcomes in individuals diagnosed with RA. These findings suggest that routine monitoring of SHBG levels in RA patients may enhance prognostic assessments and inform clinical management strategies. Key Points • SHBG represents a significant risk factor for the development of RA. • The frailty index partially mediates the relationship between SHBG and RA, explaining approximately 24.47% of this association. • Male RA patients with elevated SHBG levels experience significantly decreased survival rates.
Indexed as
Identifiers
41689735What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.